Navigation Links
ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
Date:1/31/2008

SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), announced today that data from preclinical studies of ANX-201, the Company's broad spectrum antiviral product candidate, has been accepted for presentation at the Keystone Symposia HIV Pathogenesis Conference, which takes place March 27-April 1, 2008 in Banff, Alberta. The HIV Pathogenesis Conference is part of the Keystone Symposia Global Health Series, which is supported by the Bill & Melinda Gates Foundation.

The poster presentation entitled "The pyrophosphate analogue thiophosphonoformic acid confers a favorable HIV resistance profile," is scheduled to be presented on March 30, 2008. The presentation will highlight results of in vitro infectivity assays that demonstrate a unique resistance profile for ANX-201 that suggests suppression of resistance to nucleoside reverse transcriptase inhibitors (NRTIs), a commonly used class of drugs. The potential clinical benefit of ANX-201 when used as part of combination therapy with NRTIs in resistant HIV-infected patients will also be discussed.

About ANX-201

ANX-201 (thiophosphonoformic acid) is a pyrophosphate analog and member of a new class of reverse transcriptase inhibitor (RTI) for treatment of resistant HIV-infected patients. ANX-201 has shown activity against HIV drug-resistant clinical isolates in preclinical studies. The resistance profile of ANX-201 is unique among approved RTIs and has been shown to resensitize NRTI-resistant viruses. In preclinical studies, antiretroviral activity of ANX-201 has demonstrated synergistic activity with NRTIs suggesting potential clinical benefits of combination therapy. In other preclinical studies, ANX-201 has shown broad-spectrum antiviral a
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., PHILADELPHIA,Nov.25/PRNewswire-FirstCall/--ERT(N...ey,theCompany,sPresidentandCEO,andKeithSchneck,the...topresentatthe21stAnnualPiperJaffrayHealthCareConf...York. ,, Interestedpartiesmayaccessthepresentat.../www.ert.com .Thewebcastmayalsobeaccessedat http:/...
(Date:11/25/2009)..., EXTON,Pa.,Nov.25/PRNewswire/--BioTrendsResearchG...Stelara report,thefirstinamulti-phasesyndicatedma...o-Biotech,sStelara,fromproductlaunchthroughthefirs...esquantitativeinformationfrom75uniqueDermatologist...tsassesstrialanduseofStelara,obstaclestouse,typica...
(Date:11/25/2009)..., WESTPALMBEACH,Fla.,Nov.25/PRNewswire-FirstCall/-...peciallythe27millionlivingwithuntreated hearinglos...CindyBeyer. ,, Dr.Beyer,seniorvicepresidentofHe...and hearingaids companies,saidstudieshavelinkedhea...hichcaneasilybeintensifiedatholidaygatheringswithf...
Breaking Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2iPierian Appoints Dr Matthew J Plunkett as Chief Financial Officer 13765 1iPierian Appoints Dr Matthew J Plunkett as Chief Financial Officer 13765 2Chemotherapy Linked to Sleep Wake Cycle Disruptions 55838 1Chemotherapy Linked to Sleep Wake Cycle Disruptions 55838 2National Changing Diabetes Program Supports Improvements in Health Cost Estimates 55833 1National Changing Diabetes Program Supports Improvements in Health Cost Estimates 55833 2National Changing Diabetes Program Supports Improvements in Health Cost Estimates 55833 3National Changing Diabetes Program Supports Improvements in Health Cost Estimates 55833 4National Changing Diabetes Program Supports Improvements in Health Cost Estimates 55833 5
..., 2007 /PRNewswire-FirstCall/ - Helix today,announ...udy of its,Topical Interferon Alpha-2b in women wi...ervical lesions. , The study showed a clinically e... the treated patients. In addition, the product,de...gnificant local,intolerance or drug-related seriou...
...ith Diabetes, Hospital,and Professional Charges Lo..., April 02, 2007 /PRNewswire-FirstCall/ -- The,Pit...today the,release of a new report on the prevalenc...2 diabetes. The inaugural Pittsburgh Type,2 Diabet...,demographics, hospital and professional charges, ...
Other Medicine Technology:Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b 2Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b 3Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b 4Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b 5Helix BioPharma Corp. Announces Positive Phase II Clinical Results,with its Topical Interferon Alpha-2b 6State of Diabetes in Pittsburgh: Pittsburgh Business Group on,Health Releases Report 2State of Diabetes in Pittsburgh: Pittsburgh Business Group on,Health Releases Report 3State of Diabetes in Pittsburgh: Pittsburgh Business Group on,Health Releases Report 4
(Date:11/25/2009)...eumatoid arthritis, could help newly diagnosed dia...25 (HealthDay News) -- A drug commonly used to tre... now also shows some promise in helping patients n..., rituximab (Rituxan), helped patients keep produc...ease had destroyed some of their pancreatic beta c...
(Date:11/25/2009)...ical symptoms, study finds , , WEDNESDA...ffects are among the potential problems faced by l...reated with cisplatin-based chemotherapy, a new st...gian men treated for unilateral testicular cancer ... survey conducted from 1998 to 2002. , The rese...
(Date:11/25/2009)...wire-USNewswire/--TheAmericanAssociationforHomecar....2128,whichisdesignedtosubstantiallyimprovetoolsan...lwasintroducedbySen.GeorgeLeMieux(R-Fla.). ,, T...ssociationforHomecareoutlinedinits13-pointanti-fra...inFebruary.Thoseprovisionsincludecallingforreal-ti...
(Date:11/25/2009)...ancer also can reverse a rare stomach disorder and...isease, researchers at Vanderbilt University Medic...auses thickening of the stomach lining, severe abd...a and swelling in the feet and ankles due to prote...c cancer. Previously, the only effective treatment...
(Date:11/25/2009)...hat mimicked parts of speech colored perception of...y News) -- People can "hear" not only with their e... , In fact, sensations on the skin designed to ...le decipher sounds better, the Canadian scientists...her we could use tactile information in this way,"...
Breaking Medicine News(10 mins):Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2Health News:Your Skin Can Help Your Ears Listen 2Health News:Your Skin Can Help Your Ears Listen 3
...est assesses osteoporosis risk and helps provide p...r bone health, CINCINNATI and BRIDGEWATER, N.J., ...tand your risk factors for osteoporosis, using a,n...test asks less than 20 simple questions about fami...
...nsecutive Year in Deloitte,s Technology Fast 50 Pr...stems,Inc. (Nasdaq: CASM ), a medical device comp... monitoring, today announced that it has been name...life sciences companies in the area by Deloitte & ...
...nt to Host Conference Call and Webcast Same Aftern...,BZI), a provider of functional foods, beverages a...he Company will report its financial and,operation...ernoon beginning at,4:15 PM Eastern Time, and invi...
...LIS, Oct. 19 Uroplasty, Inc. (Amex:,UPI) announce... with the,U.S. Securities and Exchange Commission ...10,000,000 (exclusive of over-allotment option) of...ic offering.,A copy of the prospectus relating to ...
...xis to Demonstrate Advanced Coronary & Peripheral ...ping at TCT 2007 Stereotaxis, Mobile Vasc...Stereotaxis, Inc. (Nasdaq:,STXS) announced today t...erapeutics (TCT) symposium in Washington,D.C., Oct...
...UGE, La., Oct. 19 Amedisys, Inc.,(Nasdaq: AMED or...lth,nursing companies, today announced that it int...ter ended September 30, 2007 pre-market on Tuesday...onference call, please dial 800-683-1525,(Domestic...
Other Medicine News:Health News:Sixty Seconds That Can Change Your Life 2Health News:Sixty Seconds That Can Change Your Life 3Health News:Sixty Seconds That Can Change Your Life 4Health News:Sixty Seconds That Can Change Your Life 5Health News:CAS Medical Systems, Inc. Ranked Among Connecticut's Fastest Growing Technology Companies 2Health News:CAS Medical Systems, Inc. Ranked Among Connecticut's Fastest Growing Technology Companies 3Health News:CAS Medical Systems, Inc. Ranked Among Connecticut's Fastest Growing Technology Companies 4Health News:XELR8 Holdings to Announce 2007 Third Quarter Results on Wednesday, October 31, 2007 2Health News:XELR8 Holdings to Announce 2007 Third Quarter Results on Wednesday, October 31, 2007 3Health News:Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock 2Health News:Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock 3Health News:Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System 2Health News:Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System 3Health News:Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System 4Health News:Amedisys to Host Conference Call to Discuss Third Quarter Financial Performance and Operating Results 2
...areCollect™ improves the specimen collection ... patient information on the handheld at the bedsid...pecific patient. Collection status information can...educe redraws, enhancing patient comfort, and maki...
...rizon Admin-Rx is a bar-code medication administra...the medication administration process with bar-cod...canner in a handheld or laptop device to verify th... at the right time in the right dosage via the rig...
wCareMed™
...diMAR™ is the newest Mediware product, which ...record. MediMAR produces a dynamic and complete re...including clinician orders, medication list, aller...ion or alerts that increase patient safety. MediMA...
Medicine Products: